Lehnhoff, Katja

177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial

Morris, M. J., Castellano, D., Herrmann, K., de Bono, J. S., Shore, N. D., Chi, K. N., Crosby, M., Piulats, J. M., Fléchon, A., Wei, X. X., et al. (2024) · The Lancet

Prostate Cancer Treatment and ResearchRadiopharmaceutical Chemistry and Applications

Cited by 362

LBA13 Phase III trial of [177Lu]Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore)

Sartor, O., Castellano Gauna, D. E., Herrmann, K., de Bono, J. S., Shore, N. D., Chi, K. N. N., Crosby, M., Piulats Rodriguez, J. M., Flechon, A., Wei, X. X., et al. (2023) · Annals of Oncology

Prostate Cancer Treatment and ResearchRadiopharmaceutical Chemistry and Applications

Cited by 71